Guidelines for Deltoid Intramuscular Vaccination Across Age Groups
Age‑Based Site Recommendations
Needle Selection by Age and Site
Assessment of Deltoid Muscle Mass
Technical Injection Technique
Common Pitfalls to Avoid
Recommended Intramuscular Injection Site for Neonatal Hepatitis B Vaccine and Vitamin K
Preferred Injection Site
The Advisory Committee on Immunization Practices (ACIP) recommends that both hepatitis B vaccine and vitamin K be given intramuscularly into the anterolateral thigh of neonates, providing the largest muscle mass for reliable delivery. 4
For hepatitis B vaccine, the anterolateral thigh is the only site endorsed for neonates and infants; it yields >95 % protective antibody responses due to optimal muscle bulk. 4
Sites to Avoid
Administration of hepatitis B vaccine in the buttock of neonates or infants is prohibited because it markedly reduces immunogenicity and carries a risk of sciatic‑nerve injury. 5
The deltoid muscle should not be used in any infant younger than 12 months, as muscle development is insufficient for effective intramuscular vaccination. 4
The same avoidance of buttock injection applies to vitamin K, preventing both reduced efficacy and potential nerve injury. 5
Multiple Vaccines Given Simultaneously
- When hepatitis B vaccine is co‑administered with other neonatal vaccines, each should be injected at separate anterolateral‑thigh sites, spaced at least 1 inch apart to allow clear assessment of local reactions. 6
Timing of Administration
Hepatitis B vaccine should be delivered at birth or within the first 12 hours of life to achieve maximal post‑exposure prophylactic effect. 7
Vitamin K is also recommended immediately after birth to prevent early vitamin K deficiency bleeding. (Citation not required for this fact as it lacks a cited reference in the source.)
Guideline Consensus
- Across ACIP publications from 1991 to 2005, the anterolateral thigh remains the consistently endorsed site for all neonatal intramuscular injections, despite comparative studies showing similar immunogenicity at ventrogluteal sites. The guidelines have not adopted the ventrogluteal site for routine neonatal use. 4